Hualv Life Science announced that the company recently received a "Notice of Shareholding Reduction Plan" issued by specific shareholder Gaotou Development. Gaotou Development plans to reduce the company's shares by no more than 6,315,400 shares in total within 3 months after 15 trading days from the disclosure date of this announcement, through centralized auction trading, which is no more than 5.36% of the company's latest total share capital, and no more than 100% of its holdings in the company. The purpose of the shareholding reduction is for shareholder asset integration, capital turnover, and its own business needs. The shareholding reduction price will be determined based on the market price at the time of implementation.